822 related articles for article (PubMed ID: 33027976)
1. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
2. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
[TBL] [Abstract][Full Text] [Related]
3. Immune Microenvironment in Glioblastoma Subtypes.
Chen Z; Hambardzumyan D
Front Immunol; 2018; 9():1004. PubMed ID: 29867979
[TBL] [Abstract][Full Text] [Related]
4. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
5. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
6. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
7. Developing immunotherapeutic strategies to target brain tumors.
Lieberman NA; Moyes KW; Crane CA
Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
[TBL] [Abstract][Full Text] [Related]
8. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
9. The immunosuppressive microenvironment and immunotherapy in human glioblastoma.
Zhang X; Zhao L; Zhang H; Zhang Y; Ju H; Wang X; Ren H; Zhu X; Dong Y
Front Immunol; 2022; 13():1003651. PubMed ID: 36466873
[TBL] [Abstract][Full Text] [Related]
10. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
11. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
[TBL] [Abstract][Full Text] [Related]
12. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
15. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
Pombo Antunes AR; Scheyltjens I; Duerinck J; Neyns B; Movahedi K; Van Ginderachter JA
Elife; 2020 Feb; 9():. PubMed ID: 32014107
[TBL] [Abstract][Full Text] [Related]
16. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
17. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
Jackson C; Ruzevick J; Phallen J; Belcaid Z; Lim M
Clin Dev Immunol; 2011; 2011():732413. PubMed ID: 22190972
[TBL] [Abstract][Full Text] [Related]
18. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
[TBL] [Abstract][Full Text] [Related]
19. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
20. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
